Medlab Clinical progresses through trials, overseas registration process
Medlab Clinical (ASX:MDC) has completed the first stage medical trials of its NanaBis product, and is encouraged by its progress with US and European medical registration administrations.
CEO Sean Hall distinguishes Medlab Clinical (ASX:MDC) from other "pot stocks" through its focus on proven medical outcomes and its breadth of products.
Hall says the company has sizeable upside as potential applications for its product include not only pain treatments but also other chronic health issues such as Type II Diabetes and depression.
CEO Sean Hall distinguishes Medlab Clinical (ASX:MDC) from other "pot stocks" through its focus on proven medical outcomes and its breadth of products.
Hall says the company has sizeable upside as potential applications for its product include not only pain treatments but also other chronic health issues such as Type II Diabetes and depression.
People In This Video
No users are tagged in this video
